High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

Abstract:

BACKGROUND:Strong acid inhibition using esomeprazole increases cure rates with triple therapy and 10-day treatments are more effective than 7-day ones. The combination of amoxicillin plus metronidazole at full doses, and using a physiologically-correct schedule three times a day, and has been shown to overcome metronidazole resistance and to achieve good eradication rates. AIMS:To assess the eradication rate of a new first-line treatment regimen associating strong acid inhibition, amoxicillin and metronidazole and to evaluate tolerance. METHODS:Patients from eight hospitals were included. Helicobacter pylori status was assessed by at least one of the following: histology, culture, rapid urease test or urea breath test (UBT). Ten-day treatment was prescribed comprising esomeprazole 40 mg twice a day plus amoxicillin 1 g and metronidazol 500 mg both three times a day. Helicobacter pylori cure was assessed by UBT. RESULTS:A hundred and thirty-six patients were enrolled. Mean age was 52.6 ± 16 years and 59.6% of patients were men. Main indications for treatment were: uninvestigated dyspepsia (13.6%); functional dyspepsia (18.2%); gastric ulcer (21.8%); and duodenal ulcer (39.8%). Helicobacter pylori eradication was achieved in 112 of the 127 patients who returned for follow-up. Eradication rates were 82.4% (95% CI: 74.7-88.1) by intention-to-treat analysis and 88.2% (95% CI: 81.2-92.8) by per protocol. Treatment was well tolerated and no major side effects were reported. Nine patients complained of mild side effects. CONCLUSIONS:Cure rates of the combination of esomeprazole, amoxicillin and metronidazole are high and the treatment was well tolerated. This pilot study warrants the comparison of this schedule with current standards.

journal_name

Aliment Pharmacol Ther

authors

Sánchez-Delgado J,García-Iglesias P,Castro-Fernández M,Bory F,Barenys M,Bujanda L,Lisozain J,Calvo MM,Torra S,Gisbert JP,Calvet X

doi

10.1111/j.1365-2036.2012.05137.x

subject

Has Abstract

pub_date

2012-07-01 00:00:00

pages

190-6

issue

2

eissn

0269-2813

issn

1365-2036

journal_volume

36

pub_type

杂志文章
  • Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.

    abstract:BACKGROUND:There is no consensus on the standard treatment of gastric mucosa-associated lymphoid tissue (MALT) lymphoma for Helicobacter pylori-negative patients and for patients with persistent disease despite H. pylori eradication. AIM:To evaluate the comparative efficacy and safety of alkylating agents and rituxima...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12635

    authors: Amiot A,Lévy M,Copie-Bergman C,Dupuis J,Szablewski V,Le Baleur Y,Baia M,Belhadj K,Sobhani I,Leroy K,Haioun C,Delchier JC

    更新日期:2014-03-01 00:00:00

  • Age-dependent eradication of Helicobacter pylori with dual therapy.

    abstract:BACKGROUND:Combined treatment using an acid-inhibiting drug with antibiotics can cure Helicobacter pylori infection. However, eradication rates are highly variable, especially if a proton pump inhibitor is used with amoxycillin. Therefore it is important to define factors/predictors of the clinical outcome. METHODS:In...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1997.00210.x

    authors: Treiber G,Ammon S,Klotz U

    更新日期:1997-08-01 00:00:00

  • Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.

    abstract::Thirteen patients with Zollinger-Ellison syndrome were investigated: 8 without, and 5 with, previous gastric surgery. After 7-34 months of treatment with famotidine, 8 out of 13 patients were resistant to this drug. Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1993.tb00086.x

    authors: Corleto V,Annibale B,D'Ambra G,Saggioro A,Ferrua B,Cassetta MR,Delle Fave G

    更新日期:1993-04-01 00:00:00

  • Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.

    abstract:BACKGROUND:Increased risk of cardiovascular and cerebrovascular disease in liver transplant recipients results in particular from the side effects of calcineurin inhibitor-based immunosuppressive therapy. Several studies have demonstrated a more favourable outcome for patients receiving tacrolimus (TAC) as compared wit...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04099.x

    authors: Beckebaum S,Klein C,Varghese J,Sotiropoulos GC,Saner F,Schmitz K,Gerken G,Paul A,Cicinnati VR

    更新日期:2009-10-15 00:00:00

  • Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

    abstract:BACKGROUND:Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. AIM:To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02755.x

    authors: Cardenas VM,Graham DY,El-Zimaity HM,Opekun AR,Campos A,Chavez A,Guerrero L

    更新日期:2006-01-15 00:00:00

  • Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model.

    abstract:BACKGROUND:Gastrimmune is an immunogenic form of gastrin. It raises in situ antibodies against two proliferative forms of gastrin: amidated and glycine-extended gastrin-17. It has been shown to have a therapeutic action in several in vivo tumour models. Following immunization, due to the complex equilibrium that exists...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01081.x

    authors: Smith AM,Morris T,Justin T,Michaeli D,Watson SA

    更新日期:2001-12-01 00:00:00

  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

    abstract:BACKGROUND:HCV-TARGET is a longitudinal observational study of chronic hepatitis C virus (HCV) patients treated with direct-acting anti-viral agents (DAAs) in a US consortium of 90 academic and community medical centres. AIM:To assess utilisation of response-guided therapy (RGT) and sustained virological response (SVR...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/apt.13095

    authors: Sterling RK,Kuo A,Rustgi VK,Sulkowski MS,Stewart TG,Fenkel JM,El-Genaidi H,Mah'moud MA,Abraham GM,Stewart PW,Akushevich L,Nelson DR,Fried MW,Di Bisceglie AM

    更新日期:2015-04-01 00:00:00

  • Evaluation of Helicobacter species in inflammatory bowel disease.

    abstract:BACKGROUND:Bacteria have been implicated in the pathogenesis of inflammatory bowel disease. Helicobacter species have been shown to cause colitis in animal models and have been identified in human diarrhoeal illness and Crohn's disease. AIM:To determine whether Helicobacter species are present in human inflammatory bo...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01703.x

    authors: Bell SJ,Chisholm SA,Owen RJ,Borriello SP,Kamm MA

    更新日期:2003-09-01 00:00:00

  • Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.

    abstract:BACKGROUND:Patients with chronic hepatitis C virus and advanced fibrosis or cirrhosis are at risk for disease progression and hepatic decompensation. AIM:To determine the effects on hepatic histology of treatment with peginterferon alfa-2a (90 or 180 mug/week) or interferon alfa-2a (3 million units three times weekly)...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2008.03620.x

    authors: Everson GT,Balart L,Lee SS,Reindollar RW,Shiffman ML,Minuk GY,Pockros PJ,Govindarajan S,Lentz E,Heathcote EJ

    更新日期:2008-04-01 00:00:00

  • Lessons from prolonged gastric pH monitoring.

    abstract::Intragastric pH monitoring has shown that the distribution of acidity within the stomach is not homogeneous. Not only is it affected by meals but it also has a circadian rhythm in which nocturnal pH falls to very acid levels in normal subjects. Although results of pH monitoring are highly reproducible within individua...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1987.tb00661.x

    authors: Bumm R,Blum AL,Bauerfeind P,Emde C

    更新日期:1987-01-01 00:00:00

  • Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.

    abstract:BACKGROUND:Infection is the most common cause of mortality in end-stage liver disease (ESLD). The impact of obesity on infection risk in ESLD is not established. AIM:To characterise the impact of obesity on infection risk in ESLD. METHODS:We evaluated the association between infection and obesity in patients with ESL...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13426

    authors: Sundaram V,Kaung A,Rajaram A,Lu SC,Tran TT,Nissen NN,Klein AS,Jalan R,Charlton MR,Jeon CY

    更新日期:2015-12-01 00:00:00

  • Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity.

    abstract:BACKGROUND:Substance P acting via the neurokinin-1 receptor is involved in the development of hyperalgesia, although studies using neurokinin-1 receptor antagonists (NK-1RA) in human somatic pain have been disappointing. AIM:To evaluate whether Substance P is involved in the development of human visceral pain/hyperalg...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2006.03190.x

    authors: Willert RP,Hobson AR,Delaney C,Hicks KJ,Dewit OE,Aziz Q

    更新日期:2007-02-01 00:00:00

  • A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.

    abstract:BACKGROUND:Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM:To assess the long-term safety and efficacy of pancrelipase (pancreatin) ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2011.04631.x

    authors: Gubergrits N,Malecka-Panas E,Lehman GA,Vasileva G,Shen Y,Sander-Struckmeier S,Caras S,Whitcomb DC

    更新日期:2011-05-01 00:00:00

  • Practice patterns for the evaluation and treatment of eosinophilic oesophagitis.

    abstract:BACKGROUND:Although consensus guidelines for eosinophilic oesophagitis have been published, it remains unclear whether gastroenterologists follow these recommendations. AIM:To assess academic and community practice patterns for the evaluation and treatment of eosinophilic oesophagitis and to compare these practices wi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2010.04476.x

    authors: Peery AF,Shaheen NJ,Dellon ES

    更新日期:2010-12-01 00:00:00

  • Review article: current management of renal dysfunction in the cirrhotic patient.

    abstract::The United Network for Organ Sharing database revealed that over the last 4-5 years, an average of 1800 patients were removed from the cadaveric waiting list annually because of patients' death and an additional 400-500 were removed from the list because of the severity of their illnesses. The pre-transplant evaluatio...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2005.02357.x

    authors: Pham PT,Pham PC,Rastogi A,Wilkinson AH

    更新日期:2005-04-15 00:00:00

  • Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation.

    abstract:AIM:To compare endoscopic banding ligation vs. no treatment in cirrhotics with intolerance or contraindications to beta-blockers for prevention of first bleeding in portal hypertension. METHODS:A sample size of 214 was planned with all sizes of varices. However, the trial was stopped due to increased bleeding in 52 pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2005.02457.x

    authors: Triantos C,Vlachogiannakos J,Armonis A,Saveriadis A,Kougioumtzian A,Leandro G,Manolakopoulos S,Tzourmakliotis D,Raptis SA,Burroughs AK,Avgerinos A

    更新日期:2005-06-15 00:00:00

  • Review article: nitroimidazole resistance in Helicobacter pylori.

    abstract::The efficacy of a nitroimidazole-containing regimen for the treatment of Helicobacter pylori infection is decreased by nitroimidazole resistance. Nitroimidazoles are meta- bolized by H. pylori by several nitro-reductases of which an oxygen-insensitive NADPH nitroreductase encoded by the rdxA gene is the most important...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00675.x

    authors: Van Der Wouden EJ,Thijs JC,Van Zwet AA,Kleibeuker JH

    更新日期:2000-01-01 00:00:00

  • Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.

    abstract:BACKGROUND:Hepatocellular carcinoma (HCC) risk after resolving chronic hepatitis B virus (HBV) infection is unclear. AIM:To compare HCC risk between Alaska Native (AN) patients with and without hepatitis B surface antigen (HBsAg) seroclearance. METHODS:We selected persons with (case-patients) and without (control-pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13621

    authors: Gounder PP,Bulkow LR,Snowball M,Negus S,Spradling PR,Simons BC,McMahon BJ

    更新日期:2016-06-01 00:00:00

  • Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures.

    abstract:BACKGROUND:The mucosa-associated microbiota appears to be highly relevant to host-microbe interactions in the gastrointestinal (GI) tract. Thus, precise characterisation of the mucosa-associated microbiota may provide important insights for diagnostic and therapeutic development. However, for technical reasons, mucosal...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13622

    authors: Shanahan ER,Zhong L,Talley NJ,Morrison M,Holtmann G

    更新日期:2016-06-01 00:00:00

  • Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

    abstract::The bioavailability of three pure 5-aminosalicylic (5-ASA) preparations (Asacol, Claversal, and Pentasa) was studied in 8 ileostomy patients and 12 normal subjects after 6 days of treatment with 2000 mg 5-ASA. The local bioavailability, reflected by the 5-ASA concentration was thereby measured at two clinically releva...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1990.tb00499.x

    authors: Christensen LA,Fallingborg J,Abildgaard K,Jacobsen BA,Sanchez G,Hansen SH,Bondesen S,Hvidberg EF,Rasmussen SN

    更新日期:1990-10-01 00:00:00

  • Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial.

    abstract:BACKGROUND:Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations. AIM:To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia patients. METHODS:Newly dia...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2006.03083.x

    authors: Mikaeli J,Bishehsari F,Montazeri G,Mahdavinia M,Yaghoobi M,Darvish-Moghadam S,Farrokhi F,Shirani S,Estakhri A,Malekzadeh R

    更新日期:2006-09-15 00:00:00

  • Review article: the burden of illness of non-cardiac chest pain.

    abstract:BACKGROUND:Non-cardiac chest pain is a common condition affecting approximately one-quarter of the population during their lifetime, but the long-term economic costs of non-cardiac chest pain are poorly defined. METHODS:A MEDLINE and Current Contents search was performed from 1991 to 2002 using specific keywords. All ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01296.x

    authors: Eslick GD,Coulshed DS,Talley NJ

    更新日期:2002-07-01 00:00:00

  • Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

    abstract:OBJECTIVE:To determine whether flumecinol (3-trifluoromethyl-alpha-ethylbenzhydrol, Zixoryn) is effective in ameliorating pruritus of cholestasis, particularly in primary bilary cirrhosis. METHODS AND RESULTS:50 patients (46 with primary biliary cirrhosis, PBC) took oral flumecinol 600 mg or identical placebo once wee...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1994.tb00297.x

    authors: Turner IB,Rawlins MD,Wood P,James OF

    更新日期:1994-06-01 00:00:00

  • Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood.

    abstract:BACKGROUND:A lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders prompts interest in new therapies. AIM:To evaluate systematically the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related functional gastrointestinal disorders in children. METHODS:MEDL...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2011.04665.x

    authors: Horvath A,Dziechciarz P,Szajewska H

    更新日期:2011-06-01 00:00:00

  • Systematic review: worldwide variation in the frequency of coeliac disease and changes over time.

    abstract:BACKGROUND:Coeliac disease (CD), originally thought to be largely confined to Northern Europe and Australasia and uncommon in North America and the Middle East, is now recognised to be equally common in all these countries. It is still thought to be rare in the Orient and Sub-Saharan Africa. AIM:To assess geographical...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12373

    authors: Kang JY,Kang AH,Green A,Gwee KA,Ho KY

    更新日期:2013-08-01 00:00:00

  • Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea.

    abstract:BACKGROUND:Travellers' diarrhoea, a common problem worldwide with significant medical impact, is generally treated with anti-diarrhoeal agents and fluid replacement. Systemic antibiotics are also used in selected cases, but these may be associated with adverse effects, bacterial resistance and drug-drug interactions. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2010.04296.x

    authors: Layer P,Andresen V

    更新日期:2010-06-01 00:00:00

  • Helicobacter pylori in children with asthmatic conditions at school age, and their mothers.

    abstract:BACKGROUND:Helicobacter pylori prevalence in Western countries has been declining simultaneously with increases in childhood asthma and allergic diseases; prior studies have linked these phenomena. AIMS:To examine the association between H. pylori colonisation in children and risk of asthma and related conditions at s...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13572

    authors: den Hollander WJ,Sonnenschein-van der Voort AM,Holster IL,de Jongste JC,Jaddoe VW,Hofman A,Perez-Perez GI,Moll HA,Blaser MJ,Duijts L,Kuipers EJ

    更新日期:2016-04-01 00:00:00

  • Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.

    abstract:BACKGROUND:The treatment of acute coronary syndromes involves a combination of antiplatelet therapies. Proton pump inhibitors are frequently recommended for patients receiving clopidogrel in addition to aspirin, to minimise the risk of bleeding. Several studies have shown that proton pump inhibitors can affect the plat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2011.04585.x

    authors: Disney BR,Watson RD,Blann AD,Lip GY,Anderson MR

    更新日期:2011-04-01 00:00:00

  • Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.

    abstract:BACKGROUND:Bodybuilding supplements can cause a profound cholestatic syndrome. AIM:To describe the drug-Induced liver injury network's experience with liver injury due to bodybuilding supplements. METHODS:Liver injury pattern, severity and outcomes, potential genetic associations, and exposure to anabolic steroids by...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15211

    authors: Stolz A,Navarro V,Hayashi PH,Fontana RJ,Barnhart HX,Gu J,Chalasani NP,Vega MM,Bonkovsky HL,Seeff LB,Serrano J,Avula B,Khan IA,Cirulli ET,Kleiner DE,Hoofnagle JH,DILIN Investigators.

    更新日期:2019-05-01 00:00:00

  • Genetic risk factors for perception of symptoms in GERD: an observational cohort study.

    abstract:BACKGROUND:Genetic polymorphisms in G-protein beta-3 subunit (GNβ3) and beta-2 adrenergic receptor (ADRB2) are associated with pain and gut hypersensitivity, which can overlap with gastroesophageal reflux disease (GERD). AIM:To evaluate relationships between single nucleotide polymorphisms (SNPs) within GNβ3 and ADRB2...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14414

    authors: Patel A,Hasak S,Nix BD,Sayuk GS,Newberry RD,Gyawali CP

    更新日期:2018-01-01 00:00:00